International Ophthalmology

, Volume 39, Issue 2, pp 485–490 | Cite as

Intravitreal dexamethasone implant as an option for anti-inflammatory therapy of tuberculosis uveitis

  • Murat HasanreisogluEmail author
  • Gokcen Gulpinar Ikiz
  • Zeynep Aktas
  • Sengul Ozdek
Case Report



Tuberculosis-associated uveitis remains a diagnostic and therapeutic challenge. After diagnosis of tuberculosis and initiation of anti-tuberculosis therapy for tuberculosis uveitis, the clinical responses are favorable. However, at 4–6 weeks of the therapy, there commonly occurs paradoxical deterioration due to an increase in inflammation which is often accompanied by cystoid macular edema. Thus, adjuvant administration of anti-inflammatory regimen should be considered. For this purpose, systemic and periocular steroids, systemic and intravitreal immunosuppressive agents have been tested. Nevertheless, there is no report in the literature about intravitreal dexamethasone slow-release implants for the treatment of this inflammatory condition.


Case presentation.


We presented a tuberculosis uveitis case whose ocular inflammation is partially modified by systemic and periocular steroid injections and then well controlled by the intravitreal dexamethasone implant.


Intravitreal dexamethasone implant injection seems to be a safe and potent option for the treatment of macular edema secondary to tuberculosis uveitis.


Tuberculosis Granuloma Uveitis Infectious Posterior uveitis Jarisch–Herxheimer reaction Dexamethasone implant Intravitreal 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Cunningham ET, Rathinam SR, Albini TA et al (2015) Tuberculous uveitis. Ocul Immunol Inflamm 23:2–6CrossRefGoogle Scholar
  2. 2.
    Gupta V, Gupta A, Rao NA (2007) Intraocular tuberculosis—an update. Surv Ophthalmol 52:561–587CrossRefGoogle Scholar
  3. 3.
    Malalis JF, Goldstein DA (2015) Advances in tuberculosis-associated uveitis. Int Ophthalmol Clin 55:37–46CrossRefGoogle Scholar
  4. 4.
    Cheung CM, Chee SP (2009) Jarisch–Herxheimer reaction: paradoxical worsening of tuberculosis chorioretinitis following initiation of antituberculous therapy. Eye 23:1472–1473CrossRefGoogle Scholar
  5. 5.
    Fonollosa A, Llorenç V, Artaraz J et al (2016) Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina 36(9):1778–1785CrossRefGoogle Scholar
  6. 6.
    Julian K, Langner-Wegscheider BJ, Haas A et al (2013) Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis. Retina 33:1943–1948CrossRefGoogle Scholar
  7. 7.
    Khurana RN, Porco TC (2015) Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina 35:1640–1646CrossRefGoogle Scholar
  8. 8.
    Fonollosa A, Valsero S, Artaraz J (2016) Dexamethasone intravitreal implants in the management of tubercular multifocal serpiginoid choroiditis. J Ophtalmic Inflamm Infect 6(1):31CrossRefGoogle Scholar
  9. 9.
    Oray M, Cakar Ozdal P, Cebeci Z, Kir N, Tugal-Tutkun I (2016) Fulminant ocular toxoplasmosis: the hazards of corticosteroid monotherapy. Ocul Immunol Inflamm. 24(6):637–646CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Ophthalmology, School of MedicineGazi UniversityAnkaraTurkey

Personalised recommendations